Skip to main content
Zura Bio Ltd logo

Zura Bio Ltd — Investor Relations & Filings

Ticker · ZURA ISIN · KYG507521071 LEI · 549300LQXD6M2MIQFN24 US Manufacturing
Open in API
Filings indexed 394 across all filing types
Latest filing 2026-05-22 Proxy Solicitation & In…
Country KY Cayman Islands
Listing US ZURA

About Zura Bio Ltd

https://zurabio.com/

Zura Bio Ltd. is a multi-asset, clinical-stage biotechnology company focused on developing novel medicines for severe autoimmune and inflammatory disorders. The company's strategy centers on dual-pathway biology, aiming to create transformative solutions for patients whose needs are not adequately met by single-pathway medicines. Its development portfolio includes the therapeutic candidates tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880). Zura Bio's mission is to enhance patient well-being by developing innovative dual-pathway antibody therapies that demonstrate efficacy, safety, and dosing convenience for challenging immunological conditions.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement
2026-05-22 English
FORM 8-K
Regulatory Filings
2026-05-22 English
8-K - Zura Bio Ltd (0001855644) (Filer)
Regulatory Filings
2026-05-07 English
10-Q - Zura Bio Ltd (0001855644) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
ARS - Zura Bio Ltd (0001855644) (Filer)
Annual Report
2026-04-30 English
8-K - Zura Bio Ltd (0001855644) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 20, 2026, for Zura Bio Limited. The key content is the announcement of the departure of the Chief Financial Officer and the appointment of a new principal financial officer. It includes details about the separation agreement and the new officer's background and compensation. Form 8-K filings are current reports used to announce major events that shareholders should know about, including changes in senior management. This document does not contain financial statements or detailed financial analysis but focuses on management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is 6025 characters, which is sufficient for a detailed announcement but not a full financial report. Hence, the classification is MANG with high confidence.
2026-04-23 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.